Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer

https://doi.org/10.17749/2070-4909.2019.12.4.279-290

Full Text:

Abstract

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors palbociclib, ribociclib and abemaciclib are the new treatment options for postmenopausal women with locally advanced or metastatic hormone-receptor (HR) positive human epidermal growth factor receptor 2 (HER2) negative BC.

The aim of the current study is to conduct complex pharmacoeconomic evaluation of using CDK4/6 inhibitors palbociclib and ribociclib that are included in Vital and Essential Drug List (VEDL) in combination with letrozole in first line treatment from the Russian healthcare system prospective.

Methods. Pharmacoeconomic evaluation consisted of two parts: clinical and economic study and budget impact analysis. We used cost minimization method for the clinical and economic study, since palbociclib and ribociclib are equally or comparably effective, according to earlier literature. Time horizon of clinical and economic study was 5 years. Direct medical costs including medications and adverse event treatments were considered. We accounted for treatment discontinuation and CDK4/6 inhibitors dose modifications. Budget impact analysis was performed for the three-year period of 2020-2022. All patients who can be treated with palbociclib or ribociclib were considered.

Results. Mean direct medical costs of using palbociclib + letrozole were 2 082 333 RUB per patient, which were 505 016 RUB or 19.5% lower, compared to ribociclib + letrozole. According to current trends of BC morbidity, 8 098-8 221 newly diagnosed patients will be ready to start treatment with CDK4/6 inhibitors in 2020-2022 in Russia annually. Using palbociclib in this patient population lowers 3-year budget costs by 9 087 million RUB or by 22.5%, compared to ribociclib.

Conclusions. Using palbociclib is the cost-saving treatment option for postmenopausal women with locally advanced or metastatic HR-positive HER2-negative BC, compared to ribociclib.

About the Authors

N. A. Avxentyev
Financial Research Institute of the Ministry of Finance of the Russian Federation; Russian Presidential Academy of National Economy and Public Administration
Russian Federation

Nikolay A. Avxentyev – Adviser at the Research Financial Institute of the Ministry of Finance; Research Fellow at the Institute of Social Analysis and Prognosis, Russian Academy of National Economy and Public Administration

Researcher ID: O-5364-2018
Scopus Author ID: 57197865322

3-2 Nastasyinsky pereulok, Moscow 127006
82 Vernadskogo prospect, Moscow 119571 



E. V. Lubennikova
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation

Elena V. Lubennikova – MD, PhD, Senior Researcher, Department of chemotherapy

24 Kashirskoye shosse, Moscow 115478



M. Yu. Frolov
Volgograd State Medical University of the Ministry of Health of the Russian Federation; Volgograd medical scientific center
Russian Federation

Maxim Yu. Frolov – MD, PhD, Associate Professor in Postgraduate Education

Researcher ID: F-8355-2015
Scopus Author ID: 35193977700

1 pl. Pavshikh Bortsov, Volgograd 400131



References

1. Kaprin A.D., Starinskii V.V., Petrova G.V. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow. 2018; 250 s. (in Russ.).

2. Kaprin A.D., Starinskii V.V., Petrova G.V. The state of cancer care in Russia in 2017. Moscow 2018; 236 s. (in Russ.).

3. Association of oncologists of Russia, Russian society of clinical Oncology: Clinical recommendations. Breast cancer. 2018; [Electronic resource]. URL: http://cr.rosminzdrav.ru/#!/recomend/236. Accessed: 05.04.2019. (in Russ.).

4. Ibransa. Instructions for medical use. State register of medicines. [Electronic resource] URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=67d19c29-05ac-4ed2-8be4-d8581505760f&t=. Accessed: 05.04.2019. (in Russ.).

5. Risarg. Instructions for medical use. State register of medicines. [Electronic resource] URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1eebf603-8a2b-4312-9267-71de1032b065&t=. Accessed: 05.04.2019. (in Russ.).

6. Order of the Government of the Russian Federation of 10.12.2018 N 2738-R. Consultant Plus. [Electronic resource] URL: http://www.consultant.ru/document/cons_doc_LAW_313085/. Accessed: 26.10.2019. (in Russ.).

7. The order of the Government of the Russian Federation of October 12, 2019 No. 2406-R. Consultant Plus. [Electronic resource] URL: http://www.consultant.ru/document/cons_doc_LAW_335635/f62ee45faefd8e2a11d6d88941ac66824f848bc2/. Accessed: 26.10.2019. (in Russ.).

8. Avksentyev N.A., Zhuravleva M.V., Pazukhina E.M., Snegovoy A.V., Frolov M.Y. Pharmacoeconomic evaluation of ribociclib for the first-line treatment of hr-positive her2-negative advanced breast cancer. Tumors of female reproductive system. 2018; 14 (2): 21-35. (In Russ.) https://doi.org/10.17650/1994-4098-2018-14-2-21-35.

9. Pavlinsky S.L., Shabalkin P.I. The use of palbocklib, a cycline-dependent kinase 4/6 inhibitor, in the treatment of metastatic breast cancer. A cost-consequence analysis. Siberian journal of oncology. 2017; 16 (4): 19-25. (In Russ.) https://doi.org/10.21294/18144861-2017-16-4-19-25.

10. Resolution of the Government of the Russian Federation of 28.08.2014 N 871 (ed. of 20.11.2018) “about the approval of Rules of formation of lists of medicines for medical application and the minimum range of the medicines necessary for rendering, medical care”. Consultant Plus. [Electronic resource] URL: http://www.consultant.ru/document/cons_doc_LAW_167999/. Accessed: 02.06.2019. (In Russ.)

11. Finn R. S. et al. Palbociclib and letrozole in advanced breast cancer. New England Journal of Medicine. 2016; 375 (20): 1925-1936.

12. Hortobagyi G. N. et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. New England Journal of Medicine. 2016; 375 (18): 1738-1748.

13. Hortobagyi G. N. et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of Oncology. 2018; 29 (7): 1541-1547.

14. Zhang T. et al. Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis. OncoTargets and therapy. 2018; 22: 2647-2656.

15. Petrelli F. et al. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. Breast cancer research and treatment. 2019; 1-8.

16. Tremblay G. et al. Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer. Cancer management and research. 2018; 10: 1319-1327.

17. Bucher H.C., Gordon H.G., Lauren E.G., Walter S.D. The Results of Direct and Indirect Treatment Comparisons in Meta-Analysis of Randomized Controlled Trials. Journal of clinical epidemiology. 1997; 50 (6): 683-691.

18. Decree of the Government of the Russian Federation of December 10, 2018 N 1506 “On the Program of state guarantees of free medical care for citizens for 2019 and for the planning period 2020 and 2021” (in Russ.).

19. Thill M., Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cance. Therapeutic Advances in Medical Oncology. 2018; 10: 1-12.

20. Snegovoi A. V., Abramov M. E., Bulavina I. S. et al. Practical recommendations for the prevention and treatment of nausea and vomiting in cancer patients. Zlokachestvennye opukholi. 2015; 4: 327-337. (In Russ.)

21. Rosstat. Population of the Russian Federation. [Electronic resource] URL: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/demography/#. Accessed: 05.04.2019. (In Russ.)

22. Rosstat. Demographic forecast to 2030 (medium version). 03.10.2018. [Electronic resource] URL: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/demography/#. Accessed: 05.04.2019. (In Russ.)


For citation:


Avxentyev N.A., Lubennikova E.V., Frolov M.Y. Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2019;12(4):279-290. (In Russ.) https://doi.org/10.17749/2070-4909.2019.12.4.279-290

Views: 92


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)